Cite
MLA Citation
J. De Bono et al.. “2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen.” European journal of cancer, vol. 51, n.d., pp. S497–. http://access.bl.uk/ark:/81055/vdc_100030628240.0x000043